FORT LEE, N.J., June 28 /PRNewswire/ -- InterCure, Ltd., today announced RESPeRATE Duo(TM), a new version of its RESPeRATE(R) -- the only non-drug treatment device clinically proven to lower blood pressure. The Duo version of RESPeRATE provides the same blood pressure-lowering benefits as the single-user RESPeRATE, but offers new memory functionality for two members of a household to personalize the device and track their progress individually, guiding each of them to a lower blood pressure.
FDA-cleared for over-the-counter sale, RESPeRATE Duo guides users through a series of paced breathing exercises that lower blood pressure by gently relaxing constricted blood vessels. Users simply listen to the melody through the headphones, and the body’s natural tendency to follow external rhythms enables the user to easily synchronize his or her breathing to the guiding tones. By gradually prolonging the exhalation tone to slow down breathing, RESPeRATE Duo leads the user to the therapeutic zone of less than 10 breaths per minute. Within a few minutes, the muscles surrounding the small blood vessels in the body relax, blood flows more freely, and blood pressure is significantly reduced. More than seven published studies show an average all-day reduction of 14/8 mm Hg within four to six weeks of daily 15 minute sessions with RESPeRATE.
RESPeRATE Duo offers both household users enhanced performance metrics for their continued use. The new product offers immediate feedback on two individuals’ use for the last session, last seven days and last 60 days. The feedback provides insight into how long each user spent breathing in the therapeutic zone, guiding them to reach their daily and weekly goals.
RESPeRATE Duo offers users additional enhancements, including: * Voice instruction -- Helping users to get started, the voice-over greets users and guides them to slower, paced breathing, enabling them to effortlessly reach the therapeutic zone. * Personalized feedback -- RESPeRATE Duo offers its users in-depth information on their use, including when users reach their therapeutic zone, how many minutes of use have elapsed in the therapeutic zone, and when each user reaches his or her session goal. The Duo model allows two users to store their performance metrics in two separate memories.
“A recent survey of RESPeRATE customers jointly conducted by Ipsos-Vantis and InterCure found that 20 percent of households have two or more members with hypertension,” said Erez Gavish, president and CEO, InterCure. “We took this feedback from our RESPeRATE customers into consideration and adapted our clinically proven technology into a device to meet the needs of two users. As a result, the Duo model is designed to help lower the blood pressure and track progress of multiple household members with hypertension to minimize the risks associated with the condition.”
More than 65 million Americans have high blood pressure. Unfortunately, even with the traditional treatment methods of diet, exercise and medication, 70 percent of that population is unable to reach their lower blood pressure goals or can not tolerate the side effects of medications. Leaving high blood pressure untreated can be dangerous and may lead to heart attack, stroke and kidney and heart failure.
Pricing and Availability
RESPeRATE Duo is available immediately online at: http://www.resperate.com/product. The Duo model is available for the introductory price of $349 per unit (list price $379).
About InterCure Ltd.
InterCure, a medical device company, has become a leader in the growing Personal Therapeutic Device category. Its broadly patented “device-guided paced breathing” technology platform, enables a systematic reduction in sympathetic outflow of the autonomous nervous system. InterCure is successfully selling the world’s 1st hypertension treatment device, RESPeRATE(R). With multiple published clinical trials, regulatory approvals in most key markets (FDA over-the-counter (“OTC”) clearance, CE mark, Chinese SDA, and others) and a renowned scientific advisory board, RESPeRATE is rapidly becoming a part of the standard of care for the treatment of hypertension. (http://www.intercure.com, http://www.resperate.com)
Contacts: Jane Hauser Judy Chodirker Schwartz Communications InterCure, Inc. 781-684-0770 201-720-7750 intercure@schwartz-pr.comjchodirker@intercure.com
InterCure, Ltd.
CONTACT: Jane Hauser of Schwartz Communications, +1-781-684-0770,intercure@schwartz-pr.com; or Judy Chodirker of InterCure, Inc.,+1-201-720-7750, jchodirker@intercure.com
